Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02749799 · ClinicalTrials.gov registry record · Phase 4
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
A Phase 4 study of Plaque Psoriasis, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
- 4
- Study locations
NCT02749799 is a Phase 4 study of Plaque Psoriasis that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 45 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02749799, a Phase 4 study of Plaque Psoriasis, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.
Conditions Studied
Interventions
- DRUG DFD-01 (betamethasone dipropionate) Spray, 0.05%
Study Locations (4)
Illinois
- Site Four - Arlington Heights
Indiana
- Site Two - New Albany
Kentucky
- Site One - Louisville
Nevada
- Site Three - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02749799
The ClinicalTrials.gov registry entry for NCT02749799 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (89% lower). The listed sponsor is Primus Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which DFD-01 (betamethasone dipropionate) Spray, 0.05% is the first listed.
NCT02749799 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Indiana, Kentucky.
Frequently Asked Questions
What is clinical trial NCT02749799 about?
NCT02749799 is a clinical study titled "Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis". The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.
What is the current status of trial NCT02749799?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2016-02. Estimated completion is 2016-08.
What conditions does trial NCT02749799 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT02749799?
The interventions under investigation include: DFD-01 (betamethasone dipropionate) Spray, 0.05% (DRUG).
Who is sponsoring clinical trial NCT02749799?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02749799 being conducted?
This trial has 4 study locations across Illinois, Indiana, Kentucky, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Guselkumab Immunogenetics
RECRUITING · Phase 4
-
Bimekizumab in Plaque Psoriasis
RECRUITING · Phase 4
-
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
COMPLETED · Phase 4
-
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
COMPLETED · Phase 4
-
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
COMPLETED · Phase 4
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.